# Stream A Phases 1-2 Cross Audit - 2026-06-08

Verdict: **GO for Phase 3**, with minor non-blocking cleanup risks.

No blocking issue was found in Stream A phases 1 and 2. Phase 1 restored the P2
global gates, and Phase 2 now separates P1/P2 unit evidence from P3/P4 release
evidence.

## Audit Inputs

- Skills used: code audit, documentation sync audit, acceptance-criteria audit.
- Sub-agent used:
  - Phase 2 documentation/acceptance sidecar: no blocker found; one wording nit
    accepted below.
  - Phase 1 sidecar: timed out and was shut down; this audit uses direct local
    verification for Phase 1 instead.
- Primary references:
  - `ARTIFACT_FRESHNESS_POLICY.md`
  - `docs/stream-a-implementation-plan-2026-06-08.md`
  - `docs/release-evidence/release-checklist-v0.1.2.md`
  - `audit/2026-06-08-stream-a-phase1-point1-artifacts-audit.md`
  - `audit/2026-06-08-stream-a-phase1-point2-p2-global-audit.md`
  - `audit/2026-06-08-stream-a-phase2-release-evidence-audit.md`

## Requirement and Acceptance Compliance

| Requirement | Status | Evidence | Problem |
| --- | --- | --- | --- |
| Phase 1 point 1.1: restore artifact freshness without bypassing policy | Respected | `.gitattributes:1` forces LF for `assets/highlight.css`; `artifacts.json:14-15` declares SHA-256 `c3c4ac152532aa6d9cfdeb8fd9562c13c432e5685ac58bf02d5a72e58760be1e` and size `1419`; local check measured the same hash and size; `npm.cmd run check:artifacts` passed. | None blocking. |
| Phase 1 point 1.2: replay P2 global gates | Respected | `npm.cmd run typecheck`, `npm.cmd test`, `npm.cmd run test:contracts`, and `npm.cmd run check:artifacts` all passed during this audit. | None blocking. |
| Phase 1 audit-after-point workflow | Respected | `audit/2026-06-08-stream-a-phase1-point1-artifacts-audit.md:3` declares GO to point 1.2; `audit/2026-06-08-stream-a-phase1-point2-p2-global-audit.md:3` declares P2 global acceptable for Phase 1 scope. | None blocking. |
| Phase 2: mark already proven P1/P2 items as unit-tested | Respected | `docs/release-evidence/release-checklist-v0.1.2.md:118-125` marks empty directory, `.MD`, verbatim `--output`, parent creation, non-writable parent error, skip summary, duplicate/collision preflight, and `--output-dir` basename collision as `pass` with unit-test evidence. | None blocking. |
| Phase 2: keep P3/browser/PDF proof unaccepted | Respected | `docs/release-evidence/release-checklist-v0.1.2.md:66-67` keeps integration and browser-backed tests `blocked`. | None blocking. |
| Phase 2: keep P4/install/FR-19/FR-20/FR-21 proof pending | Respected | `docs/release-evidence/release-checklist-v0.1.2.md:87-91`, `:97-100`, `:107-108`, and `:129` keep FR-20, packaging/install, README comparison, and FR-19/FR-21 evidence pending. | None blocking. |

## Negative Findings

### Finding 1 - Phase 2 Audit Overstates One Evidence Range

Severity: Low

File: `audit/2026-06-08-stream-a-phase2-release-evidence-audit.md`

Line: 22

Problem: The audit says unit proof is recorded at
`docs/release-evidence/release-checklist-v0.1.2.md:63-68`, but that range also
contains blocked P3 integration/browser rows at lines 66-67.

Risk: A reader could briefly misunderstand the evidence map and think the P3
blocked rows are part of the unit-proof set.

Evidence: `docs/release-evidence/release-checklist-v0.1.2.md:63-65` records P2
global gates, `:66-67` records P3 blockers, and `:68` records artifact
freshness. The actual checklist content is correct; the imprecision is in the
audit wording.

Suggested fix: In a follow-up cleanup, reword the audit line to cite unit/P2
proof as `:63-65`, `:68`, `:106`, and `:118-125`, with P3 blockers separately
at `:66-67`.

Test needed: Documentation-only review; no runtime test needed.

### Finding 2 - The Plan Referenced By The Audits Is Still Untracked

Severity: Low

File: `docs/stream-a-implementation-plan-2026-06-08.md`

Line: 1

Problem: `git status --short` shows
`docs/stream-a-implementation-plan-2026-06-08.md` as untracked, but the phase
audits and checklist updates rely on it as the normative plan.

Risk: If the final change set omits this plan, the new audit reports point at a
source document that does not exist in the committed repository.

Evidence: `git status --short` reports
`?? docs/stream-a-implementation-plan-2026-06-08.md`; the phase audits cite that
path as their requirement source.

Suggested fix: Include the plan file in the final committed/reviewed change set
or move the citations to a tracked equivalent source.

Test needed: `git status --short` before commit/review.

### Finding 3 - Checklist EOL Warning Is Non-Blocking But Noisy

Severity: Low

File: `docs/release-evidence/release-checklist-v0.1.2.md`

Line: 1

Problem: `git diff` warns that LF will be replaced by CRLF the next time Git
touches the checklist.

Risk: This is not an artifact freshness issue, but it can add noisy future diffs
or make line-sensitive audit references less pleasant to review.

Evidence: `git diff -- docs/release-evidence/release-checklist-v0.1.2.md`
emitted `LF will be replaced by CRLF`.

Suggested fix: Decide whether docs should use repo-wide EOL normalization. This
does not need to block Stream A Phase 3.

Test needed: None for Phase 1/2 acceptance.

## Validation Replayed

```text
npm.cmd run typecheck
PASS

npm.cmd test
PASS - 9 test files, 80 tests

npm.cmd run test:contracts
PASS - 1 test file, 11 tests

npm.cmd run check:artifacts
PASS - Artifact freshness policy passed.

assets/highlight.css
size: 1419
sha256: c3c4ac152532aa6d9cfdeb8fd9562c13c432e5685ac58bf02d5a72e58760be1e
```

## Remaining Gaps

- Stream A P3 remains blocked until the runtime path no longer uses the public
  `convertFile` `NotImplementedError` stub.
- Browser-backed PDF/Mermaid tests remain blocked by P3.
- P4 packaging/install evidence, FR-19, FR-20, FR-21, README/help comparison,
  and final release decision remain pending by design.

## Summary

Phases 1 and 2 are acceptable. The current change set fixes the artifact gate,
proves the P2 global gates, and updates the release checklist without falsely
accepting P3/P4 evidence. The only issues found are documentation hygiene risks,
not blockers for moving to Phase 3.
